Cassava Sciences, Inc.
General ticker "SAVA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $116.7M (TTM average)
Cassava Sciences, Inc. does not follow the US Stock Market performance with the rate: -20.9%.
Estimated limits based on current volatility of 2.8%: low 0.93$, high 0.99$
Factors to consider:
- Total employees count: 20 (-33.3%) as of 2025
- Top business risk factors: Regulatory and compliance, Clinical trial delays, Manufacturing supply issues, Intellectual property risks, Cybersecurity threats
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.54$, 4.09$]
- 2026-12-31 to 2027-12-31 estimated range: [1.62$, 4.23$]
Financial Metrics affecting the SAVA estimates:
- Positive: with PPE of -1.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -30.98 <= 0.30
- Positive: 42.34 < Shareholder equity ratio, % of 62.86 <= 63.79
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of -0.56 > -0.65
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term SAVA quotes
Long-term SAVA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $105.96MM | $141.45MM | $95.39MM |
| Operating Income | $-105.96MM | $-141.45MM | $-95.39MM |
| Non-Operating Income | $8.74MM | $117.10MM | $4.42MM |
| R&D Expense | $89.42MM | $69.64MM | $26.59MM |
| Income(Loss) | $-97.22MM | $-24.34MM | $-90.97MM |
| Net Income(Loss)* | $-97.22MM | $-24.34MM | $-90.97MM |
| Stockholders Equity | $137.47MM | $145.70MM | $74.40MM |
| Assets | $151.66MM | $157.53MM | $118.36MM |
| Operating Cash Flow | $-82.03MM | $-116.93MM | $-32.25MM |
| Capital expenditure | $0.41MM | $0.10MM | $0.58MM |
| Investing Cash Flow | $-0.41MM | $-0.10MM | $-0.58MM |
| Financing Cash Flow | $2.56MM | $124.47MM | $-0.24MM |
| Earnings Per Share** | $-2.32 | $-0.53 | $-1.88 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.